Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2023-08-01 Regulatory Filings
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
Trading Halt 2 pages 208.0KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Mesoblast Limited regarding a trading halt requested pending an upcoming announcement related to the FDA's review of a Biologics License Application. It is a short notice about the trading halt and does not contain financial data, management discussion, or detailed report content. It is an announcement about a trading halt, not a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance notices that do not fit other categories.
2023-08-01 English
6-K
Regulatory Filings
2023-08-01 English
F-6EF
Regulatory Filings
2023-07-31 English
Change in substantial holding 8 pages 554.7KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 604 Notice of change of interests of substantial holder' under the Corporations Act 2001 Section 671B. It details changes in voting power and shareholdings of a substantial holder, M&G Plc and its subsidiaries, including dates and amounts of share sales and purchases. This type of filing is a notification of changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (MRQ). The document is lengthy and contains detailed transaction data, not just an announcement or summary, confirming it is the actual notification. Therefore, the appropriate classification is MRQ.
2023-07-31 English
6-K
Regulatory Filings
2023-07-31 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 488.6KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED JUNE 30, 2023' and contains detailed quarterly cash flow statements, including operating, investing, and financing activities. It references ASX Listing Rule 4.7B, which mandates quarterly cash flow reporting. The document includes actual financial data such as cash balances, payments, receipts, and reconciliations for the quarter ended June 30, 2023. It is not merely an announcement or a brief summary but a comprehensive quarterly financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2023-07-30 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.